Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Yuan Pin Hung, Jen Chieh Lee, Chun Wei Chiu, Ching Chi Lee, Pei Jane Tsai, I. Lin Hsu, Wen Chien Ko

研究成果: Article同行評審

2 引文 斯高帕斯(Scopus)

摘要

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir/ritonavir within five days of symptom onset. Moreover, good oral availability enables the usage of nirmatrelvir/ritonavir, not only in hospitalized patients, but also among outpatients. Nirmatrelvir (PF-07321332) has been demonstrated to stop the spread of COVID-19 in animal models. Despite frequent mutations in the viral genomes of SARS-CoV-2, nirmatrelvir shows an effective antiviral effect against recent coronavirus mutants. Despite the promising antiviral effect of nirmatrelvir, there are several unresolved concerns. First, the final results of large-scale clinical trials for early therapy of mild cases of COVID-19 are not yet published. Second, the effectiveness of nirmatrelvir against upcoming variants in the coming years requires close monitoring. Considering the promising preliminary results of the EPIC-HR trial, nirmatrelvir/ritonavir in conjunction with vaccines and non-pharmacological interventions, may represent the dawn in the dark of the COVID-19 pandemic.

原文English
文章編號220
期刊Antibiotics
11
發行號2
DOIs
出版狀態Published - 2022 2月

All Science Journal Classification (ASJC) codes

  • 微生物學
  • 生物化學
  • 藥理學、毒理學和藥劑學 (全部)
  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)

指紋

深入研究「Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?」主題。共同形成了獨特的指紋。

引用此